BioNTech (NASDAQ:BNTX) Trading 7.5% Higher – Should You Buy?

BioNTech SE Sponsored ADR (NASDAQ:BNTX)’s stock price shot up 7.5% during trading on Wednesday . The stock traded as high as $114.33 and last traded at $113.4330. 644,844 shares changed hands during trading, a decline of 34% from the average session volume of 972,646 shares. The stock had previously closed at $105.56.

Analyst Ratings Changes

A number of research firms have weighed in on BNTX. Bank of America decreased their price target on BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a report on Wednesday, October 22nd. Morgan Stanley reissued an “overweight” rating and set a $134.00 target price on shares of BioNTech in a research report on Monday, November 3rd. TD Cowen restated a “hold” rating on shares of BioNTech in a research note on Monday, November 3rd. Berenberg Bank reaffirmed a “buy” rating on shares of BioNTech in a report on Friday. Finally, The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $115.00 to $142.00 in a report on Friday, January 16th. Eleven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $140.03.

BioNTech Stock Down 2.1%

The stock has a market capitalization of $26.12 billion, a price-to-earnings ratio of -44.10 and a beta of 1.40. The firm’s fifty day moving average is $99.39 and its 200-day moving average is $103.74. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.12 and a quick ratio of 7.02.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of $0.75 by ($0.89). The company had revenue of $1.78 billion for the quarter, compared to analyst estimates of $1.21 billion. BioNTech had a negative return on equity of 3.03% and a negative net margin of 17.91%.BioNTech’s revenue was up 22.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.81 earnings per share. On average, sell-side analysts predict that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

Institutional Trading of BioNTech

Institutional investors and hedge funds have recently bought and sold shares of the company. Dodge & Cox lifted its stake in BioNTech by 315.7% during the third quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock worth $359,676,000 after purchasing an additional 2,769,654 shares during the last quarter. BNP Paribas Financial Markets increased its stake in BioNTech by 6.7% during the second quarter. BNP Paribas Financial Markets now owns 1,275,475 shares of the company’s stock valued at $135,800,000 after purchasing an additional 80,005 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of BioNTech by 58.8% during the second quarter. Bank of New York Mellon Corp now owns 1,108,719 shares of the company’s stock worth $118,045,000 after purchasing an additional 410,351 shares during the period. Franklin Resources Inc. raised its holdings in shares of BioNTech by 76.8% during the second quarter. Franklin Resources Inc. now owns 751,998 shares of the company’s stock worth $80,065,000 after purchasing an additional 326,556 shares during the period. Finally, Aberdeen Group plc lifted its position in shares of BioNTech by 87.2% in the 2nd quarter. Aberdeen Group plc now owns 721,928 shares of the company’s stock worth $76,864,000 after buying an additional 336,260 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.